Zealand Pharma A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zealand Pharma A/S
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
Revenues are still elusive for a surprising number of the novel drugs approved by the FDA five years ago. Emergent safety issues and confirmatory clinical trial failures were less common than lack of competitiveness as the main reason for revenue weakness.
- Other Names / Subsidiaries
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.